The Laboratory of Molecular Neurooncology is located at the Department of Neurology of the University Hospital Zurich (Frauenklinikstrasse 26, CH-8091 Zurich). The Laboratory is led by Prof. Dr. M. Weller together with Prof. Dr. P. Roth, and Dr. M. Silginer (organisational chart). Dr. T. Weiss and Dr. H.G. Wirsching have acquired independent research funding and lead junior research teams.
Major research areas of the laboratory include cancer immunology and immunotherapy, mechanisms of migration, invasion and angiogenesis, and resistance to therapy in brain tumors.
Major goals of our cancer immunology research include the characterization of immunological characteristics of glioma cells, in particular of putative tumor stem cells. We explor transforming growth factor beta (TGF-beta)-mediated pathways and TGF-beta-targeting therapeutics and develop novel concepts of immunotherapy involving, immunocytokines and immune checkpoint inhibition. The Clinical Research Priority Program (CRPP) "ImmunoCure" represents an interdisciplinary consortium of research groups exploring novel immunotherapeutic approaches with the focus on chimeric antigen receptor (CAR)-T cells as targeted immunotherapeutic strategy. In addition, studies on the primary and acquired resistance of glioma cells to radiotherapy and chemotherapy are conducted. In cooperation with the Department of Neurosurgery (Prof. Dr. L. Regli), a tumor bank with tumor tissue for histology and molecular analyses as well as for the isolation and characterization of tumor-derived glioma stem cells and novel projects focused on gene editing as a novel approach of gene therapy have been established..
In the area of clinical neurooncology, we founded, together with the partner institutions of neuroradiology, neurosurgery, nuclear medicine, neuropathology, radiation oncology, medical oncology and pediatric neurooncology, the
Brain Tumor Center Zurich at the Comprehensive Cancer Center Zurich in January 2012.
In cooperation with the Centers of the German Glioma Network (www.gliomnetzwerk.de) and the European Organization for Research and Treatment of Cancer (EORTC), we are involved in several clinical pathological molecular correlative projects looking at, e.g. prognostic and predictive value of molecular markers such as 1p 19q codeletion, MGMT promotor methylation and isocitrate dehydrogenase mutations in different glioma entities and long-time survival in glioblastoma.
The laboratory has been supported by the Brain Tumor Funder Collaborative in the US, Swiss National Science Foundation, Oncosuisse, the Zurich Cancer League, the Wilhelm Sander-Foundation, the EMDO Foundation, the Hartmann-Müller Foundation, the Koetser Foundation, the Sophien Foundation, the Desirée und Nils Yde Foundation, the foundation “Stiftung für Angewandte Krebsforschung” and the German Research Foundation and performs cooperative research projects with the pharmaceutical companies Apogenix (Heidelberg), Novocure (Jersey Isle), Philogen (Siena) und Quercis (Zug).
Department of Neurology and Laboratory for Molecular Neuro-Oncology
University Hospital Zurich
here to see the structural organisation chart.
You will find the list of group members on the following
here to see the organisation chart of the laboratory teams.
Current scientific projects
Schweizerischer Nationalfond (SNF)
The role of interferon type I signalling in the malignant phenotype and response to immune checkpoint inhibition in glioblastoma
TERT promoter mutation: a novel predictive biomarker in gliolastoma?
Novel combinations of immunotherapy and radiotherapy for the treatment of primary and secondary brain tumors
Stiftung für angewandte Krebsforschung
A novel integrative approach to characterize and exploit the proteomic landscape in metastatic lung cancer
Klinischer Forschungs-schwerpunkt (KFSP)
Oncosuisse / Swiss Cancer League
lntegrins as targets for advanced chimeric antigen receptor (CAR) T cell treatment of glioblastoma
Desirée and Niels Yde Foundation
Evolution of the genomic-immunologic landscape of glioblastoma under chemoradiotherapy
Current clinical trials
Global Principal Investigator
Contact in Zurich
(EORTC 1608-BTG), phase Ib
TGO2 in elderly newly diagnosed or adult relapsed patients with anaplastic astrocytoma or glioblastoma
Arm A and B: Newly diagnosed anaplastic astrocytoma or glioblastoma (>65 years)
Arm C: Recurrent anaplastic astrocytoma or glioblastoma (>18 years)
|Prof. Dr. P. Roth|
recruiting (Arm A and B)
completed (Arm C)
(EORTC 1635), phase III
IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat?
|EORTC||Prof. Dr. Martin van den Bent, Rotterdam|
IDH mutated 1p/19q intact lower grade glioma
PERGOLA, phase II
Pembrolizumab for newly diagnosed glioblastoma: a prospective, open-label, single-arm, multicenter phase II study
|University of Zurich|
Prof. Dr. P. Roth, Zurich
CheckMate 548, phase III
Study of temozolomide plus radiation therapy with nivolumab or placebo, for newly diagnosed patients with glioblastoma
Newly diagnosed glioblastoma, methylated MGMT promotor
(EORTC-1709-BTG), phase III
Multicenter study of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma
Prof. Dr. P. Roth, Zurich
Newly diagnosed glioblastoma
Gliosun, phase I/II
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma
Newly diagnosed glioblastoma
Gliostar, phase I/II
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with recurrent glioblastoma
Dr. T. Weiss, Zurich
Glioblastoma at first recurrence
Dr. T. Weiss
Gliomoon, phase I/II
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF in patients with IDH wildtype WHO grade III /IV glioma at first relapse
IDH wildtype WHO grade III /
IV glioma at first relapse
Agios AG881-C-004, phase III
Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation
BLZ945, PDR001, phase II
BLZ945 single agent or BLZ945 in combination with PDR001 in patients with recurrent isocitrate dehydrogenase (IDH) wild-type glioblastoma
Radiation versus observation following surgical resection of atypical meningioma
Prof. M. D. Jenkinson, Liverpool, Prof. Dr. M. Preusser
newly diagnosed atypical meningeoma (WHO grade II)
Prof. Dr. N. Andratschke
CDI-CS-003, phase I/IIa
BAL101553 in patients with advanced solid tumors or recurrent glioblastoma
Dr. Thomas Kaindl,
BGB-290-104, phase I/IIa
Multicenter study to assess the safety, tolerability
and efficacy of BGB-290 in combination with radiation
therapy and/or temozolomide in patients with newly diagnosed
or recurrent glioblastoma
Newly diagnosed glioblastoma, unmethylated MGMT promotor or recurrent glioblastoma
Prof. Dr. M. Weller
Dr. K. Seystahl
Dr. H.G. Wirsching
Fitness to drive for Glioblastoma patients after standard therapy
Glioblastoma patients, without tumor progression after standard therapy or 6 months after diagnosis and without history of seizures within the last 12 months
IOSI-RTO-001, phase II
Stereotactic Radiosurgery or Hypofractionated ImageGuided Radiotherapy to the surgical cavity after resection of brain metastases: a multicenter, single arm, open-label trial
Istituto Oncologico della Svizzera Italiana (IOSI)
Dr. med. Gianfranco A. Pesce, Bellinzona
Patients after surgical resection of a single brain metastasis (primary tumor: lung, breast, melanoma, kidney, colorectal cancer) or single cases of surgical resected brain metastasis and another not resected lesion
ReSurge, phase II
Randomized Controlled Comparative Phase II Trial on Surgery for Glioblastoma Recurrence
complete removal of contrast-enhancing lesion considered feasible
Completed PhD research projects
Completed projects of PhD students of our laboratory are listed below. Related publications can be found by the following link.
Integrin inhibition interferes with TGF-beta signaling in malignant glioma cells
How stem-like are sphere cultures from long-term cancer cell lines?
Growth and differentiation factor (GDF)-15, microRNA and the immunophenotype of glioblastoma
Characterizing CD317 as a novel target for chimeric antigen receptor (CAR) T cell therapy in glioblastoma
TMZ resistance in glioblastoma
Modulation of cerebral endothelial cell function by Glioma-Derived factors
The Role of TGF-β Coreceptors in Glioblastoma
Co-inhibition of the TGF-β and VEGF pathways in glioblastoma
Crosstalk between the Met and TGF-β pathways in glioblastoma
Focused ultrasound-mediated delivery of encapsulated MGMT antagonists for the treatment of temozolomide-resistant glioblastoma
Extracellular control of TGF-beta signaling in glioblastoma
Growth factor signalling in glioblastoma
Modulation of glioblastoma biology by type I interferons
Characterisation and exploitation of the NKG2D system in glioblastoma
Please follow the link to the detailed list of publications
Donations for our scientific work can be made via bank transfer to either of the following accounts:
Transfer to our postal giro account: Recipient: Rechnungswesen der Universität Zürich 8001 Zürich, giro account no.: 80-643-0, IBAN: CH46 0900 0000 8000 0643 0, BIC: POFICHBEXXX
Transfer to our bank account: Recipient: Universität Zürich CH-8001 Zürich, account no. 1100-0109.594 (BC 700) - Zürcher Kantonalbank, CH-8010 Zürich, Swift-Code: ZKBKCHZZ80A, IBAN: CH51 0070 0110 0001 0959 4
For accounting purposes we would like to ask you to add the "payable to" notice as follows: "Zu Gunsten des Kontos F-86001-01-01". If you want to choose the intended purpose in detail, please contact us before or after your bank transfer (tel.
+41 44 255 55 00). We will be pleased to send you an official confirmation of your donation by simply contacting us via our telephone number
+41 44 255 55 00.